Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Kailera Therapeutics, Inc. (KLRA) AI Forecast

Our AI analyzed Kailera Therapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$KLRA Neutral Signal Full forecast available
Sign Up Free

Kailera Therapeutics, Inc. (KLRA) Stock Forecast Aug. 25, 2026

Kailera Therapeutics, Inc. (KLRA) AI Stock Price Forecast & Investment Analysis

Kailera Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Kailera Therapeutics, Inc. (KLRA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Kailera Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on August 25, 2026, 10:04 p.m. (UTC)

Kailera Therapeutics, Inc. Investment Summary

When evaluating whether Kailera Therapeutics, Inc. (KLRA) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Kailera Therapeutics, Inc. (KLRA) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $2 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Kailera Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Kailera Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Kailera Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Kailera Therapeutics, Inc.

Sign Up Free
Corporate Identity

Kailera Therapeutics, Inc. (Stock Symbol: KLRA) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Kailera Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Kailera Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Kailera Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Kailera Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Kailera Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Kailera Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Kailera Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Kailera Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Kailera Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Kailera Therapeutics, Inc. strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Kailera Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 11.11 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Kailera Therapeutics, Inc. (KLRA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Kailera Therapeutics, Inc. stock analysis.

Deep dive into Kailera Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Kailera Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Kailera Therapeutics, Inc.:

P/B Ratio 1.92x
Market Cap $2.14B
Book Value/Share $8.63
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Kailera Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Kailera Therapeutics, Inc.:

Understanding Financial Health Metrics

What these metrics mean: These ratios assess Kailera Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Kailera Therapeutics, Inc.: A current ratio of 11.11 indicates strong liquidity.

Current Ratio 11.11x
D/E Ratio 0.08x
Financial Leverage 1.08x
Working Capital $846M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Kailera Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Kailera Therapeutics, Inc.:

Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Kailera Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Kailera Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Kailera Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Kailera Therapeutics, Inc.:

Income Statement
Operating Income -$84M
Net Income -$78M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 929%
Cash & Short-term Investments 130%
Total Liabilities 93%
Short-term Debt 64%
Dividend & Shareholder Information
Shares Outstanding 130M

Latest Kailera Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Kailera Therapeutics, Inc. (KLRA) stock price and investment outlook.

📰 Loading...

Where KLRA sits on the market map

Explore the map →

Kailera Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Kailera Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
AAGH ██% N/A x x
AARD ██% $159M x 2.1x
ABBV ██% $469.99B 74.5x x
ABCL ██% $3.83B x 4.3x
ABEO ██% $355M x 2.8x
ABT ██% $202.24B 32.2x 3.9x
ABUS ██% $1.03B 6.7x 4.0x
ABVC ██% $21M x 2.0x
ABVX ██% $9.26B x x
ACAD ██% $5.26B 13.8x 4.0x
ACET ██% $84M x 0.7x
ACRS ██% $914M x 7.3x
ACRV ██% $93M x 1.1x
ACUT ██% $3M x x
ACXP ██% $7M x 0.8x
ADAG ██% $252M x 6.7x
ADCT ██% $133M x x
ADIL ██% $15M x x
ADTX ██% $6M x x
ADXN ██% $5M x x
AEON ██% $11M x x
AGIO ██% $2.02B x 2.0x
AKBA ██% $260M x 10.4x
AKTX ██% $15M x 0.8x
ALDX ██% $94M x 2.5x
ALKS ██% $8.24B 124.7x 4.6x
ALLR ██% $21M x 6.0x
ALMS ██% $3.06B x 6.8x
ALNY ██% $32.11B 40.0x 23.7x
ALT ██% $622M x 1.3x
ALXO ██% $276M x 2.0x
ALZN ██% $8M x 10.5x
AMLX ██% $4.17B x 17.4x
AMPH ██% $935M 11.9x 1.2x
AMRN ██% $299M x 0.7x
AMRX ██% $5.72B 36.4x 173.2x
ANAB ██% $1.69B x 132.9x
ANEB ██% $13M x 1.6x
ANIP ██% $1.60B 14.8x 2.7x
ANIX ██% $124M x 8.6x
ANNX ██% $1.04B x 5.6x
ANRO ██% $1.42B x 6.5x
ANTX ██% $206M x 2.7x
ANVS ██% $78M x x
APLM ██% $77M x x
APRE ██% $12M x 0.3x
APUS ██% $8M x 0.1x
APVO ██% $4M x 0.7x
AQST ██% $638M x x
ARCT ██% $439M x 2.6x
ARDX ██% $942M x 6.3x
ARQT ██% $3.12B 109.5x 14.2x
ARTL ██% $3M x 0.7x
ARVN ██% $627M 67.4x 1.1x
ARWR ██% $12.54B x 27.0x
ASBP ██% $12M x 1.0x
ASMB ██% $701M x 2.3x
ASND ██% $15.68B x x
ASRT ██% $151M x 2.0x
ATAI ██% $2.76B x 17.3x
ATHE ██% $81M x x
ATNM ██% $34M 1.3x 1.1x
ATOS ██% $27M x 1.0x
ATXI ██% $1M x 2.3x
AUPH ██% $2.23B 7.1x 3.6x
AVBP ██% $1.48B x 4.0x
AVIR ██% $436M x 2.1x
AVTX ██% $1.06B x 2.4x
AXIM ██% $1M x x
AXSM ██% $10.75B x 129.0x
AZTR ██% $10M x 1.3x
BBIO ██% $15.83B x x
BBOT ██% $732M x 2.3x
BCAX ██% $1.55B x 3.3x
BCTX ██% $30M x 1.3x
BCYC ██% $306M x 0.6x
BDPT ██% $20K x x
BDRX ██% $1M x x
BFRG ██% $10M x 1.5x
BFRI ██% $21M x 3.5x
BHC ██% $2.50B x x
BHST ██% $46M x 1.8x
BIOA ██% $434M x 1.2x
BIOE ██% $13M 8.9x 5.7x
BIOM ██% $520K x x
BIVI ██% $18M x 1.8x
BIXT ██% $2M x x
BLRX ██% $12M x x
BLTE ██% $6.25B x 8.1x
BMEA ██% $119M x 9.8x
BMRN ██% $12.59B 172.6x 2.0x
BMY ██% $137.39B 14.8x 6.2x
BNTC ██% $437M x 2.4x
BOLD ██% $66M x 1.0x
BOLT ██% $7M x 0.6x
BPTH ██% $2M x x
BQST ██% $2M x x
BRNS ██% $25M x 0.4x
BSPK ██% $10K x x
BTAI ██% $25M x x
BYSI ██% $29M x x
CALC ██% $17M x 3.1x
CANF ██% $7M x 1.3x
CAPR ██% $472M x 1.9x
CATX ██% $364M x 1.1x
CBIO ██% $641M x 5.9x
CDT ██% $2M x 0.0x
CING ██% $79M x 3.4x
CLCS ██% $65M x x
CLNN ██% $57M x x
CLRB ██% $24M x 0.8x
CLSDQ ██% $1M x x
CLYM ██% $942M x 3.9x
CMMB ██% $17M x 1.4x
CMND ██% $2M x x
CMPS ██% $2.01B x 23.8x
CNBX ██% N/A x x
CNSP ██% $9M x 0.5x
CNTA ██% $6.27B x 12.9x
CNTB ██% $145M x 5.4x
CNTX ██% $43M x 1.1x
COCP ██% $22M x 21.0x
COGT ██% $6.22B x 11.7x
COLL ██% $896M 18.7x 2.9x
CORT ██% $12.88B 233.5x 18.3x
COYA ██% $114M x 2.6x
CPHI ██% $38M x 1.1x
CPIX ██% $126M x 7.2x
CPMD ██% $1M x x
CPRX ██% $3.85B 17.4x 3.8x
CRBP ██% $194M x 1.9x
CRMD ██% $637M 3.4x 1.4x
CRNX ██% $8.97B x 7.5x
CRVO ██% $40M x 1.7x
CRVS ██% $1.19B x 5.3x
CTMX ██% $741M x 2.5x
CTNM ██% $623M x 2.6x
CTOR ██% $85M x 2.1x
CTTH ██% $3M x 4.5x
CTXR ██% $16M x 0.2x
CUE ██% $203M x 88.1x
CURX ██% $7M x 1.5x
CVKD ██% $5M x 1.2x
CVSI ██% $4M x 2.5x
CYCN ██% $17M x 3.3x
CYDY ██% $295M x x
CYPH ██% $181M x 1.3x
CYRX ██% $828M x 1.7x
CYTK ██% $10.68B x x
DARE ██% $16M x x
DCOY ██% $2M x 0.5x
DERM ██% $212M x 6.6x
DMAC ██% $352M x 9.2x
DMRA ██% $1.90B x 3.7x
DNTH ██% $6.09B x 5.2x
DRMA ██% $8M x 2.3x
DRUG ██% $756M x x
DSGN ██% $953M x 4.7x
DWTX ██% $86M x 1.3x
DYN ██% $4.93B x 7.0x
EBS ██% $261M x 0.8x
EDSA ██% $42M x 4.8x
ELAB ██% $5M x 0.3x
ELAN ██% $11.97B x 1.8x
ELDN ██% $276M x 8.4x
ELTP ██% $309M 5.5x 3.0x
ELTX ██% $78M x 9.9x
ELVN ██% $4.49B x 5.0x
EMMA ██% $3M x x
ENLV ██% $26M 0.0x 0.0x
ENSC ██% $7M x x
ENTA ██% $417M x 4.1x
ENVB ██% $6M x 0.8x
EOLS ██% $554M x x
EPRX ██% $444M x 5.4x
EQ ██% $140M x 2.5x
ERAS ██% $6.22B x 17.2x
ERNA ██% $6M x 1.8x
ESPR ██% $799M x x
ETON ██% $1.82B 143.7x 39.1x
ETST ██% $31M 7.0x 4.2x
EVFM ██% $1M x x
EVMN ██% $496M x 1.8x
EWTX ██% $4.83B x 10.8x
FBIO ██% $98M 0.9x 0.6x
FBLG ██% $9M x 1.9x
FBRX ██% $1.58B x 8.6x
FHTX ██% $403M x x
FLNA ██% $45M x 0.7x
FTH ██% $897M x 5.2x
FULC ██% $293M x 0.9x
GALT ██% $391M x x
GANX ██% $84M x 7.4x
GCAN ██% $250K 0.3x x
GDTC ██% $12M x x
GENB ██% $2.27B x 5.0x
GERN ██% $986M x 4.5x
GHRS ██% $1.74B x x
GLMD ██% $4M x 0.3x
GLSI ██% $245M x 78.5x
GNLX ██% $123M x 7.6x
GNPX ██% $3M x 0.2x
GOSS ██% $86M x x
GOVX ██% $4M x 2.0x
GPCR ██% $3.49B x 2.6x
GRCE ██% $46M x 1.0x
GRI ██% $4M x 0.4x
GRTX ██% $3.38B 22.7x 4646.0x
GSK ██% $103.71B x x
GTBP ██% $13M x 3.6x
GYRE ██% $701M x 6.5x
HCM ██% $2.12B 2.3x 1.7x
HCWB ██% $4M x 0.7x
HELP ██% $920M x x
HEPA ██% $6M x 4.3x
HIND ██% $16M x 2.6x
HOOK ██% $14M x 0.4x
HOWL ██% $42M x 2.6x
HRMY ██% $2.24B 12.3x 2.2x
HRTX ██% $61M x 8.8x
HSTC ██% $92M x 74.2x
HURA ██% $127M x 6.9x
HYFT ██% $66M x x
HYPD ██% $50M 7.5x 0.5x
IBIO ██% $71M x 0.9x
IBO ██% $49M 61.8x 4.5x
IDYA ██% $3.82B x 3.2x
IFRX ██% $309M x x
IGC ██% $31M x 5.0x
IMMP ██% $57M x x
IMMX ██% $974M x 4.3x
IMNM ██% $3.18B x 6.1x
IMNN ██% $9M x 2.2x
IMRN ██% $9M x x
IMRX ██% $335M x 1.8x
IMUX ██% $225M x 1.8x
INBP ██% $5M x 0.3x
INDP ██% $146M x 12.8x
INDV ██% $4.39B 14.2x x
INM ██% $8M x 1.1x
INO ██% $129M x 29.6x
INSM ██% $27.06B x 35.7x
INTI ██% $15M x x
INVA ██% $1.53B 3.8x 1.2x
IOBTQ ██% $10K x 0.0x
IONS ██% $10.28B x 23.4x
IRD ██% $333M x x
IRON ██% $3.10B x 4.8x
IRWD ██% $720M 5.5x x
ISCO ██% $4M x x
IVA ██% $1.11B x x
IXHL ██% $43M x 0.6x
JAGX ██% $4M x 0.6x
JANX ██% $1.06B x 1.2x
JAZZ ██% $16.08B 17.1x 3.4x
JBIO ██% $1.36B x 3.1x
JNJ ██% $657.32B 31.3x 7.7x
JUNS ██% $7M x x
KALA ██% $15M x 1.7x
KALV ██% $1.38B x x
KAPA ██% $5M x 1.2x
KAYS ██% $70K x x
KLRA ██% $2.14B x 1.9x
KMDA ██% $475M x x
KNSA ██% $6.07B 83.1x 10.0x
KPRX ██% $10M x 0.7x
KPTI ██% $44M x x
KROS ██% $228M x 0.9x
KRRO ██% $194M x 1.9x
KTTA ██% $17M x 0.3x
KURA ██% $1.10B x 22.8x
KYNB ██% $30M 0.2x x
LAB ██% $255M 3.0x 0.5x
LABT ██% $5M x 1.2x
LBRX ██% $1.56B x 4.7x
LEGN ██% $4.07B x x
LEXX ██% $17M x 3.7x
LFCR ██% $171M x x
LFVN ██% $86M 10.9x 2.6x
LGND ██% $5.70B 28.9x 5.9x
LGVN ██% $27M x 2.6x
LIANY ██% $12M x 0.1x
LIFD ██% $1M x 0.2x
LIPO ██% $0.00M x 0.0x
LITS ██% $36M x 0.6x
LIXT ██% $120M x 15.2x
LKFT ██% $1.91B x x
LLY ██% $1.12T 41.9x 33.1x
LNAI ██% $10M x x
LPCN ██% $17M x 0.8x
LQDA ██% $6.29B 45.4x 32.2x
LRMR ██% $421M x 3.3x
LSTA ██% $16M x 2.0x
LTRN ██% $27M x x
LXRX ██% $1.04B x 5.9x
LYEL ██% $345M x 1.5x
MAIA ██% $85M x 4.1x
MANE ██% $4.11B x 5.1x
MBIO ██% $4M x 0.6x
MBRX ██% $12M x 1.0x
MBX ██% $3.18B x 7.8x
MCRB ██% $45M x 1.3x
MDCX ██% $16M x x
MDGL ██% $11.77B x 22.5x
MEDS ██% $4M x 0.1x
MGNX ██% $261M x 6.1x
MIRA ██% $33M x 4.1x
MIRM ██% $6.35B x x
MIST ██% $145M x 8.0x
MLTX ██% $1.34B x 3.1x
MLYS ██% $2.33B x 4.2x
MNKD ██% $1.29B x x
MNOV ██% $75M x 2.0x
MNPR ██% $745M x 5.7x
MPLT ██% $509M x 1.5x
MREO ██% $46M x 1.6x
MRK ██% $376.80B 118.8x 9.0x
MRKR ██% $25M x 2.1x
MRVI ██% $3.12B x 15.3x
MSLE ██% $212M x x
MTNB ██% $3M x 1.6x
MTVA ██% $11M x 1.6x
NAMS ██% $3.16B x 5.0x
NATR ██% $252M 13.9x 1.5x
NBP ██% $231M x 0.9x
NBTX ██% $2.11B x x
NCEL ██% $20M x 36.6x
NCNA ██% $6M x x
NERV ██% $227M x x
NEUP ██% $21M x 0.7x
NGNE ██% $793M x 3.7x
NIKA ██% $442M x x
NKTR ██% $2.52B x 2.8x
NKTX ██% $193M x 0.8x
NMAD ██% $76M x 3.2x
NNVC ██% $32M x 3.5x
NRIX ██% $2.77B x 6.9x
NRSN ██% $14M x x
NRXP ██% $154M x x
NSRX ██% $48M x 17.3x
NTHI ██% $122M x x
NUVB ██% $2.34B x 9.2x
NUVL ██% $9.75B x 8.3x
NVCT ██% $779M x 85.8x
NVS ██% $301.53B x x
NWBO ██% $286M x x
NXTC ██% $27M x 2.3x
NXTS ██% $3M x 1.4x
OCUL ██% $2.43B x 4.7x
OGEN ██% $2M x 0.6x
OGI ██% $178M x x
OGN ██% $3.61B 17.3x 3.6x
OKUR ██% $157M x 0.9x
OLMA ██% $935M x 2.2x
OMER ██% $1.39B 11.2x x
ONC ██% $42.36B 64.6x 8.2x
ONCO ██% $2M x 0.2x
ONCY ██% $105M x x
OPK ██% $1.12B x 0.9x
ORGO ██% $215M x 1.5x
ORIC ██% $1.39B x 3.7x
ORKA ██% $6.25B x 5.6x
ORMP ██% $199M 1.1x 0.6x
OSTX ██% $72M x x
OTLC ██% $18M x 0.1x
OVID ██% $521M x 2.5x
OWPC ██% $10K x x
PAHC ██% $1.43B 15.0x 4.0x
PBH ██% $2.44B 14.2x 1.3x
PBM ██% $16M x x
PBYI ██% $466M 17.4x 3.4x
PCRX ██% $982M 67.1x 1.5x
PCSA ██% $6M x x
PCYN ██% $2M x 1.0x
PDSB ██% $12M x x
PEPG ██% $221M x 1.9x
PFE ██% $159.97B 36.9x 1.9x
PGEN ██% $2.58B x 59.2x
PHAT ██% $710M x x
PHIO ██% $14M x 1.1x
PHVS ██% $2.62B x x
PKTX ██% $80K x 0.3x
PLRX ██% $71M x 0.5x
PLYX ██% $93M x 8.5x
PMHS ██% $6M x x
PMN ██% $133M x 2.7x
PMVP ██% $70M x 1.0x
PPBT ██% $3M x x
PPCB ██% $3M x 0.3x
PRAX ██% $10.27B x 7.7x
PRFX ██% $3M x 0.4x
PRGO ██% $1.98B x 0.8x
PRLD ██% $528M x 4.0x
PRPH ██% $310K x x
PRQR ██% $330M x x
PRTA ██% $486M x 1.7x
PTCT ██% $5.92B x x
PTGX ██% $10.01B 120.7x 11.9x
PTIX ██% $2M x 1.2x
PTN ██% $18M x 1.7x
PTPI ██% $170K x 0.2x
PULM ██% $6M x 2.2x
PVCT ██% $25M x x
PVLA ██% $2.04B x 9.4x
PYXS ██% $257M x 22.5x
QNRX ██% $11M x 2.8x
QNTM ██% $21M x x
QTTB ██% $487M 14.4x 4.6x
QUCY ██% $110M x 5.4x
QURE ██% $2.99B x 20.0x
RADX ██% $19M x x
RANI ██% $124M x 3.2x
RAPP ██% $2.37B x 5.6x
RARE ██% $2.54B x x
RCKT ██% $387M x 1.1x
RCUS ██% $3.83B x 8.2x
RDY ██% $10.20B x x
REGN ██% $85.17B 19.7x 2.7x
REVB ██% $4M x 0.4x
RFL ██% $112M x 1.5x
RGBP ██% $170K x x
RIGL ██% $836M 2.6x 2.0x
RKTO ██% $17M x 2.0x
RLMD ██% $481M x 2.3x
RLYB ██% $89M 2.0x 0.9x
RMHI ██% $25M x x
RMTI ██% $32M x 0.9x
RNAC ██% $302M x x
RNAZ ██% $3M x x
RNTX ██% $67M x 1.2x
RNXT ██% $56M x 6.3x
ROIV ██% $26.28B x 6.2x
RPRX ██% $35.26B 43.3x 5.2x
RTEZ ██% $1.93B x x
RVPH ██% $7M x 0.4x
RVRC ██% $87M x 15.7x
RYTM ██% $7.67B x 74.5x
RZLT ██% $482M x 4.1x
SBFM ██% $4M x 0.2x
SCNX ██% $19M x 0.3x
SCYX ██% $52M x 0.8x
SDGR ██% $1.40B x 4.3x
SEPN ██% $1.82B x 4.7x
SER ██% $67M x 3.6x
SGMT ██% $631M x 2.5x
SHPH ██% $2M x 0.6x
SIGA ██% $213M x 1.3x
SILO ██% $5M x 0.9x
SION ██% $252M x 1.0x
SKVI ██% $970K x x
SKYE ██% $10M x x
SLGL ██% $251M x 11.0x
SLN ██% $826M x 21.5x
SLS ██% $2.89B x 21.0x
SMMT ██% $10.10B x 16.0x
SMNR ██% $143M x x
SNDX ██% $1.73B x 114.7x
SNGX ██% $9M x 1.3x
SNSE ██% $31M x x
SNY ██% $109.48B x x
SPRB ██% $157M x 1.9x
SPRC ██% $154M x x
SPRO ██% $71M 9.6x 1.6x
SPRY ██% $527M x 42.1x
SRPT ██% $1.94B 6.3x 1.3x
STOK ██% $2.02B x 5.8x
STTK ██% $796M x 3.8x
SUPN ██% $2.62B x 2.5x
SVRA ██% $1.14B x 8.0x
SXTP ██% $4M x 1.5x
SYBX ██% $14M x 1.2x
SYRE ██% $9.61B x 8.7x
TAK ██% $58.28B x x
TBPH ██% $882M 16.4x 3.1x
TCRT ██% $4M x 6.8x
TELO ██% $81M x 16.1x
TENX ██% $83M x 0.7x
TEVA ██% $42.93B 60.8x 5.5x
TGTX ██% $8.32B 18.8x 13.8x
TLPH ██% $63M x 4.3x
TLX ██% $3.96B x x
TNGX ██% $4.05B x 4.0x
TNXP ██% $224M x 1.0x
TOVX ██% $11M x 0.9x
TPST ██% $18M x x
TRDA ██% $291M x 1.3x
TRVI ██% $2.59B x 8.1x
TTRX ██% $289M x 420.4x
TVRD ██% $24M x 2.9x
TVTX ██% $6.13B x 249.8x
TXMD ██% $26M x 0.9x
TYRA ██% $1.61B x 4.5x
UNCY ██% $153M x 2.9x
UPB ██% $380M x 1.4x
URGN ██% $2.25B x x
UTHR ██% $22.15B 16.9x 3.5x
VBIO ██% $630K x 0.2x
VCNX ██% $3M x x
VERA ██% $2.49B x 6.1x
VGLS ██% $240K x x
VICP ██% $47M x x
VKTX ██% $3.85B x 9.4x
VNDA ██% $320M x 1.5x
VRCA ██% $85M x 19.6x
VRDN ██% $2.75B x 4.2x
VREOD ██% $491M x 1.7x
VREOF ██% $491M x 1.7x
VRTX ██% $139.15B 31.6x 6.9x
VSTM ██% $645M x 12.9x
VTGN ██% $10M x 0.4x
VTRS ██% $19.29B 7.3x 1.4x
VYNE ██% $19M x 0.8x
WHWK ██% $283M x 1.6x
WVE ██% $1.03B x 2.3x
XBIO ██% $9M x 1.5x
XBIT ██% $69M x 0.5x
XCUR ██% $7M x 7.4x
XENE ██% $5.86B x 4.7x
XERS ██% $1.52B x x
XLO ██% $61M x 0.8x
XNCR ██% $2.19B x 4.4x
XOMA ██% $710M 21.0x 7.7x
XTLB ██% $6M x x
ZBIO ██% $2.01B x 8.2x
ZLAB ██% $2.95B x 4.9x
ZNTL ██% $360M x 2.5x
ZTS ██% $31.94B 12.2x 10.2x
ZVRA ██% $695M 11.3x 3.2x
ZVSA ██% $810K x x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Kailera Therapeutics, Inc. Stock Forecast

How accurate are Kailera Therapeutics, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for KLRA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Kailera Therapeutics, Inc. stock price forecasts?

Our analysis considers Kailera Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Kailera Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Kailera Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Kailera Therapeutics, Inc. forecasts updated?

Kailera Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Kailera Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...